Trinity Biotech Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Trinity Biotech.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Medical Equipment earnings growth | 16.2% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
Recent updates
Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%
Mar 02Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry
Dec 18A Look At The Fair Value Of Trinity Biotech plc (NASDAQ:TRIB)
Sep 12Should You Investigate Trinity Biotech plc (NASDAQ:TRIB) At US$0.80?
Aug 08Insufficient Growth At Trinity Biotech plc (NASDAQ:TRIB) Hampers Share Price
Jun 09Calculating The Intrinsic Value Of Trinity Biotech plc (NASDAQ:TRIB)
Apr 23This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts
Apr 23Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?
Mar 01Trinity Biotech appoints former GE executive Aris Kekedjian as CEO
Oct 03At US$1.22, Is Trinity Biotech plc (NASDAQ:TRIB) Worth Looking At Closely?
Sep 01Trinity Biotech GAAP EPADS of -50c, revenue of $18.78M misses by $1.22M
Jun 30Returns Are Gaining Momentum At Trinity Biotech (NASDAQ:TRIB)
Jun 14Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?
Mar 23Is Trinity Biotech plc (NASDAQ:TRIB) Popular Amongst Insiders?
Feb 25Trinity Biotech plc (NASDAQ:TRIB) Could Be Less Than A Year Away From Profitability
Feb 02A Treatise On Trinity Biotech
Jan 13Did You Miss Trinity Biotech's (NASDAQ:TRIB) Impressive 241% Share Price Gain?
Jan 05What Do The Returns At Trinity Biotech (NASDAQ:TRIB) Mean Going Forward?
Dec 10Trinity Biotech (NASDAQ:TRIB) Takes On Some Risk With Its Use Of Debt
Nov 19Trinity Biotech EPS beats by $0.22, beats on revenue
Nov 17In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Trinity Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2023 | 57 | -37 | -14 | -12 | N/A |
9/30/2023 | 71 | -39 | -13 | -10 | N/A |
6/30/2023 | 72 | -42 | -8 | -5 | N/A |
3/31/2023 | 74 | -34 | -7 | -2 | N/A |
12/31/2022 | 75 | -41 | -7 | -1 | N/A |
9/30/2022 | 76 | -32 | -6 | 2 | N/A |
6/30/2022 | 79 | -22 | -5 | 3 | N/A |
3/31/2022 | 86 | -13 | -2 | 6 | N/A |
12/31/2021 | 93 | 1 | 5 | 13 | N/A |
9/30/2021 | 106 | -8 | 11 | 20 | N/A |
6/30/2021 | 116 | -2 | 18 | 27 | N/A |
3/31/2021 | 106 | -2 | 19 | 29 | N/A |
12/31/2020 | 102 | -6 | 14 | 24 | N/A |
9/30/2020 | 91 | -20 | -1 | 7 | N/A |
6/30/2020 | 83 | -27 | -6 | 5 | N/A |
3/31/2020 | 90 | -31 | -2 | 10 | N/A |
12/31/2019 | 90 | -29 | -6 | 5 | N/A |
9/30/2019 | 94 | -30 | -4 | 11 | N/A |
6/30/2019 | 93 | -29 | -7 | 9 | N/A |
3/31/2019 | 95 | -23 | -7 | 9 | N/A |
12/31/2018 | 97 | -23 | -10 | 7 | N/A |
9/30/2018 | 97 | -39 | -10 | 7 | N/A |
6/30/2018 | 99 | -40 | -8 | 8 | N/A |
3/31/2018 | 99 | -40 | -6 | 10 | N/A |
12/31/2017 | 99 | -39 | -7 | 9 | N/A |
9/30/2017 | 98 | -36 | N/A | 8 | N/A |
6/30/2017 | 99 | -37 | N/A | 10 | N/A |
3/31/2017 | 100 | -36 | N/A | 8 | N/A |
12/31/2016 | 100 | -39 | N/A | 10 | N/A |
9/30/2016 | 101 | 3 | N/A | 17 | N/A |
6/30/2016 | 101 | 16 | N/A | 14 | N/A |
3/31/2016 | 98 | 16 | N/A | 13 | N/A |
12/31/2015 | 100 | 22 | N/A | 13 | N/A |
9/30/2015 | 101 | 23 | N/A | 15 | N/A |
6/30/2015 | 103 | 15 | N/A | 17 | N/A |
3/31/2015 | 105 | 17 | N/A | 16 | N/A |
12/31/2014 | 105 | 15 | N/A | 16 | N/A |
9/30/2014 | 103 | 18 | N/A | 8 | N/A |
6/30/2014 | 100 | 10 | N/A | 6 | N/A |
3/31/2014 | 95 | 10 | N/A | 8 | N/A |
12/31/2013 | 91 | 10 | N/A | 9 | N/A |
9/30/2013 | 86 | 9 | N/A | 15 | N/A |
6/30/2013 | 83 | 17 | N/A | 17 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if TRIB's forecast earnings growth is above the savings rate (2.4%).
Earnings vs Market: Insufficient data to determine if TRIB's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if TRIB's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if TRIB's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if TRIB's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TRIB's Return on Equity is forecast to be high in 3 years time